ArticleInflammatory bowel diseases2023
Alterations in the Fungal Microbiome in Ulcerative Colitis.
Article in Inflammatory bowel diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 20 citations in OpenAlex.
- Fungal abundance across flare and remission in ulcerative colitis patients.Gut pathogens · 2026Article
- Ecological patterns of the gut mycobiome and microbiome in ulcerative colitis across life stages.Frontiers in cellular and infection microbiology · 2026Article
- Short-chain fatty acids in ulcerative colitis: integrating metabolic fate, dynamic biomarkers, and precision delivery.Frontiers in nutrition · 2026Review
- One therapy, many targets: redefining ulcerative colitis treatment through fecal microbiota transplantation.Therapeutic advances in gastroenterology · 2026Review
- Recent Advancement of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis- A Review.Current medicinal chemistry · 2026Review
- Article
- Protective Properties of the White Button Mushroom, Agaricus bisporus, in a Mouse Model of Colitis.Molecular nutrition & food research · 2025Article
- Exploring diet-microbiota interactions and therapeutic nutrition management in inflammatory bowel disease.Biophysics reports · 2025Article
- The gastrointestinal mycobiome in inflammation and cancer: unraveling fungal dysbiosis, pathogenesis, and therapeutic potential.Medical oncology (Northwood, London, England) · 2025Review
- The Role of Intestinal Fungi in the Pathogenesis and Treatment of Ulcerative Colitis.Microorganisms · 2025Review
- Specific Bacterial Co-abundance Groups Are Associated With Inflammatory Status in Patients With Ulcerative Colitis.Journal of Crohn's & colitis · 2025Article
- Gut fungal profile in new onset treatment-naïve ulcerative colitis in Saudi children.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Dental problems and oral microbiome alterations in ulcerative colitis.Frontiers in immunology · 2025Review
- Role ofWorld journal of gastroenterology · 2024Review
- Article
- Assessing robotic-assisted surgery versus open approach in penetrating Crohn's disease: advantages and outcomes in ileocolic resection.Techniques in coloproctology · 2024Article
- Hesperetin Alleviated Experimental Colitis via Regulating Ferroptosis and Gut Microbiota.Nutrients · 2024Article
- Dynamics of the Gut Mycobiome in Patients With Ulcerative Colitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
- Microbial butyrate capacity is reduced in inflamed mucosa in patients with ulcerative colitis.Scientific reports · 2024Article
- A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAlthough gut fungi have been implicated in the immunopathogenesis of inflammatory bowel disease, the fungal microbiome has not been deeply explored across endohistologic activity and treatment exposure in ulcerative colitis.
methodsWe analyzed data from the SPARC IBD (Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease) registry. We evaluated the fungal composition of fecal samples from 98 patients with ulcerative colitis across endoscopic activity (n = 43), endohistologic activity (n = 41), and biologic exposure (n = 82). Across all subgroups, we assessed fungal diversity and differential abundance of taxonomic groups.
resultsWe identified 500 unique fungal amplicon sequence variants across the cohort of 82 patients, dominated by phylum Ascomycota. Compared with endoscopic remission, patients with endoscopic activity had increased Saccharomyces (log2 fold change = 4.54; adjusted P < 5 × 10-5) and increased Candida (log2 fold change = 2.56; adjusted P < .03). After adjusting for age, sex, and biologic exposure among patients with endoscopic activity, Saccharomyces (log2 fold change = 7.76; adjusted P < 1 × 10-15) and Candida (log2 fold change = 7.28; adjusted P< 1 × 10-8) remained enriched during endoscopic activity compared with quiescence.
conclusionsEndoscopic inflammation in ulcerative colitis is associated with an expansion of Saccharomyces and Candida compared with remission. The role of these fungal taxa as potential biomarkers and targets for personalized approaches to therapeutics in ulcerative colitis should be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.